Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.29M Buy
9,098
+464
+5% +$159K 0.99% 44
2026
Q1
$3.04M Buy
8,634
+151
+2% +$53.8K 1% 43
2025
Q4
$2.78M Buy
8,483
+98
+1% +$31.1K 0.97% 44
2025
Q3
$2.37M Buy
8,385
+256
+3% +$74.2K 0.87% 51
2025
Q2
$2.27M Buy
8,129
+277
+4% +$78.5K 0.91% 48
2025
Q1
$2.45M Buy
7,852
+366
+5% +$108K 1.09% 34
2024
Q4
$1.95M Buy
7,486
+742
+11% +$220K 0.88% 46
2024
Q3
$2.17M Buy
6,744
+494
+8% +$162K 0.96% 42
2024
Q2
$1.95M Buy
6,250
+731
+13% +$215K 1% 41
2024
Q1
$1.57M Buy
5,519
+3,133
+131% +$917K 0.85% 50
2023
Q4
$344K Buy
2,386
+1,202
+102% +$328K 0.2% 82
2023
Q3
$318K Buy
+1,184
New +$295K 0.2% 85

Other funds holding AMGN

Slagle Financial's AMGN Position: Q2 2026 in Review

Slagle Financial increased its Amgen (AMGN) stake by 5.4% in Q2 2026, buying an estimated $159K and bringing the position to 9,098 shares worth $3.29M. The position accounts for 0.99% of the portfolio, ranked #44.

Slagle Financial first reported a position in AMGN in Q3 2023 and has held it in 12 quarters since. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Slagle Financial held 9,098 shares of Amgen worth $3.29M as of Q2 2026.
  • Slagle Financial bought 464 Amgen shares in Q2 2026, an estimated $159K.
  • Amgen made up 0.99% of Slagle Financial's portfolio in Q2 2026, its #44 holding.
  • Slagle Financial first reported a position in Amgen in Q3 2023 and has held it in 12 quarters since.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Slagle Financial's 13F filing for Q2 2026, filed 29 Jul 2026.